SummaryRMgm-4513
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 30146157 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Gao H, Yuan J |
Name Group/Department | State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signal Network |
Name Institute | School of Life Sciences, Xiamen University |
City | Xiamen, Fujian |
Country | China |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4513 |
Principal name | Δisp1 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Ookinetes are formed in wild type numbers. Many ookinetes with aberrant morphology. |
Oocyst | Strongly reduced oocyst formation (mean of 8 oocysts per mosquitoe compared to 100 oocyst in wild type infected mosquitoes). |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Additional information genes tagged: genes deleted: Mutated GCβ Analyses of these mutants showed the following (from the Abstract): Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1212600 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1011000 | ||||||||||||||||||||||||
Gene product | phosphodiesterase delta, putative | ||||||||||||||||||||||||
Gene product: Alternative name | isp1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||
Additional remarks genetic modification | CRISPR/Cas9 plasmid pYCm was used for parasite genomic modification. To construct the vectors for gene deleting, we amplified the 5'- and 3'- genomic sequence (400 to 700 bp) of target genes as left and right homologous arms using specific primers and inserted into the restriction sites in pYCm. Oligonucleotides for guide RNAs (sgRNAs) were annealed and ligated into pYCm. For each gene, two sgRNAs were designed to target the coding region of gene using the online program ZiFit. To construct the vectors for gene tagging and T2A insertion, we first amplified the C- or N-terminal segments (400 to 800 bp) of the coding regions as left or right arm and 400 to 800 bp from 5' UTR or 3' UTR following the translation stop codon as left and right arm, respectively. A DNA fragment (encoding mCherry, mScarlet, 6HA, 4Myc, or 3V5 tag) was inserted between the left and right arms in frame with the gene of interest. For each gene, two sgRNAs were designed to target sites close to the C- or N-terminal part of the coding region. To construct vectors for site-directed nucleotide mutations, the substitution sites were designed with a restriction site for modification detection and placed in the middle of the homologous arms. Parasite-infected red blood cells (RBC) were electroporated with 5 mg purified circular plasmid DNA using the Lonza Nucleotector. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |